Introduction
In lung adenocarcinoma, as in other types of cancer, gene amplification and the consequent overexpression of the amplified oncogene play an important role in the development of tumors, because their overexpression confers a growth advantage. The ability to identify putative oncogenes that are activated during tumorigenesis could facilitate the choice of molecular genetic targets for diagnosis and therapy of the disease. This concept has been exemplified by HER-2, which was first found to be amplified in neuroblastomas and subsequently shown to be associated with poor prognosis in breast cancer (Ross and Fletcher, 1999) . Now, HER-2 aberrations are used as a predictor of response to therapy, and treatment of HER-2-positive breast cancer with the monoclonal anti-HER-2 antibody trastuzumab has been shown to improve prognosis (Ross and Fletcher, 1999) . Emerging evidence of common amplicons in lung adenocarcinomas (Luk et al., 2001; Jiang et al., 2004; Tonon et al., 2005) suggests that additional oncogenes remain to be identified; however, conventional techniques are ineffective in pinpointing such oncogenes. Parallel measurement of DNA copy number and mRNA levels in cDNA microarrays permits changes in copy number to be compared with transcription levels on a gene-by-gene basis to generate lists of candidate genes within the defining amplicons (Hyman et al., 2002; Pollack et al., 2002) . However, use of transcript patterns does not allow assessment of the expression of protein products or identification of protooncogenes. Another approach, identifying differentially expressed proteins by proteomic analysis and then comparing the proteins present with mRNA expression in cDNA microarrays from the same specimens, can clarify the extent to which changes in transcript patterns reflect changes in their cognate proteins and posttranscriptional mechanisms (Chen et al., 2002) , but this approach cannot be used to identify oncogenes driven by extensive increases of their gene copy number. Moreover, using individual microarrays or proteomic approaches alone cannot distinguish the cancer-driving oncogenes that directly propel tumor progression from the larger number of passenger genes that may be concurrently over-represented but are not biologically relevant in tumor development.
In this study, we used a comprehensive approach that integrated simultaneous comparative genomic hybridization (CGH) and transcript microarray with proteomic analyses of six lung adenocarcinoma cell lines. We directly and specifically identified four putative oncogenes that could have been activated through amplification and consequent elevation of transcript expression. We used small interfering RNA (siRNA) to inhibit the expression of two of these four genes in the lung cancer cell lines, which further implicated them in oncogenesis. We then explored the clinical significance of these findings by assessing the expression of these two genes in tissue microarrays of human lung cancer specimens. Our findings underscore the power of integrated functional genomic analyses for identifying putative oncogenes in tumorigenesis; such activated genes could be useful as targets for diagnosis or therapy in lung cancer.
Results
Simultaneous global genomic and transcript analyses identify 183 genes with increases in genomic copy numbers and transcript expression levels To identify genes in which increased DNA copy number might contribute to increased transcript in lung adenocarcinomas, first we used CGH with microarrays of six lung adenocarcinoma cell lines. We identified 587 genes showing increases in DNA copy number across all six cell lines (Supplementary Table 1S ), which were distributed as 90 amplicons on all chromosomes except for chromosomes 13 and Y (Supplementary Table 2S) . A subsequent transcript test with the identical arrays of the same cell lines revealed 275 genes that showed increased mRNA levels (Supplementary Table 3S ). Using random permutation tests across all cancer cell lines, we identified 183 genes (31%) that showed elevated transcript levels from the 587 genes that were over-represented in the genome (Table 1 ), suggesting that elevated transcript levels of the 183 genes may reflect their genomic over-representation in the cancer cells. These findings are consistent with previous reports linking genomic changes with altered transcript patterns in breast cancer (Hyman et al., 2002; Pollack et al., 2002) . However, our finding that only 31% of the genes showing increased DNA copy numbers had cognate increases in transcript expression in lung adenocarcinomas is different from the overall rates of 40-60% reported for breast cancer (Hyman et al., 2002; Pollack et al., 2002) . This discordance may reflect methodologic differences between studies or biological differences between breast cancer and lung adenocarcinoma.
Proteomic analyses identify four genes for which protein abundance was associated with increases in the cognate gene and transcript levels Analysis of transcript patterns is insufficient for understanding the expression of protein products and the effect of genomic over-representation on the expression of their cognate proteins. To extend these findings beyond genomic over-representation to expression of the protein products of those genes, we next assessed protein expression in the same cell lines by twodimensional polyacrylamide gel electrophoresis (PAGE) and found that 42 different proteins, representing 42 individual genes, were significantly increased in the cancer cell lines (Table 2 ; Supplementary Figures 1S and  2S) . Some of these proteins were identified as having multiple isoforms, and all individual isoforms exhibited increases in expression ranging from 4.6 to 12.8 times their expression in normal lung tissue cells. In comparing protein level of the 42 genes with changes in their cognate genomic and mRNA expression from the global microarray analyses, we found that four (9.5%) of those 42 genes -PRDX1, EEF1A2, CALR, and KCIP-1 -showed statistically significant correlations between elevated protein expression and increases in both copy number and mRNA expression (all r>0.84; Po0.05) (Table 2) in the cancer cell lines. These findings imply that the abundance of these four proteins is attributable to the amplification and consequent elevated transcription of their cognate genes.
Validation of copy number, transcript, and protein expression of PRDX1, EEF1A2, CALR, and KCIP-1 in lung cancer cell lines To confirm our findings from the high-throughput analyses, we next used Southern, Northern, and Western blotting to assess DNA, RNA, and protein levels for the four genes identified in the six cell lines. For comparison, we arbitrarily chose one gene, NFKB1, in which an increase in protein level did not correlate with genetic changes. Overall, we found excellent concordance between the CGH microarray and Southern blotting analyses, transcript array and Northern blotting analyses, and proteomic and Western blotting analyses for all five genes (Figure 1 ). For example, KCIP-1 showed fivefold amplification in five of the six cancer cell lines, whereas NFKB1 showed no such increase in any of the cell lines. As for transcript expression, Northern blotting of EEF1A2 showed high expression in five of the six cancer cell lines; again, levels of NFKB1 transcript were not increased in any cancer cell line as compared with normal bronchial epithelial cells. The results of Western blotting were also consistent with the results of the proteomic experiments; for example, five of the cancer cell lines exhibited strong protein bands for PRDX1 as compared with normal cells. These findings provide strong support for the validity of the results derived from the high-throughput techniques in this study.
These parallel analyses also revealed close correlations in the extent of changes in gene copies, transcript, and protein of each of the four genes in the cancer cell lines. For example, in the five cancer cell lines that showed at least fourfold increases in EEF1A2 copy number, expression of transcript and protein was also increased by at least a factor of four as well (relative to their expression in normal cells) (Supplementary Figure  3S) . The protein abundance of the four genes showing Identifying oncogenes in lung adenocarcinoma R Li et al corresponding increases in both DNA copy number and mRNA provides further evidence that these could be oncogenes, the activation of which is reflected by genomic amplification and consequent increases in transcript level in lung adenocarcinoma cell lines. Figure 5S) . Apoptosis of siRNAtransfected cells was 27-34%, whereas only 4% of the same cell lines treated with PBS or scrambled siRNA showed apoptosis. These results strongly support an oncogenic role for the identified genes in lung cancer and confirm their potential usefulness as therapeutic targets for the disease. (Figure 2 ). We next examined whether overexpression of these genes was associated with increased cell proliferation by analysing Ki-67 expression in contiguous sections of the tissue microarrays. Positive Ki-67 expression was found to correlate with positive expression of both KCIP-1 (P ¼ 0.02) and EEF1A2 (P ¼ 0.01). To extend these findings, we then studied 11 tissue microarray blocks comprising normal and tumor tissue specimens from 113 patients with pathologic stage I non-small-cell lung cancer who had undergone curative surgery (Wang et al., 2005) . Immunohistochemical analysis showed that EEF1A2 was expressed in 32 cases (28%) and KCIP-1 in 29 cases (26%). Univariate and multivariate Cox proportional hazards models were used to detect possible associations between EEF1A2 and KCIP-1 expression and clinicopathologic variables. Expression of EEF1A2 or KCIP-1 was associated with short overall survival time (P ¼ 0.0012 for EEF1A2 and P ¼ 0.0026 for KCIP-1) (Supplementary Figure 6S) . Age at diagnosis, histologic type of cancer, degree of tumor differentiation, and smoking history were not associated with survival time.
Although only two genes were validated in the lung tissue microarrays (because available antibodies to the other two genes were not suitable for use in Identifying oncogenes in lung adenocarcinoma R Li et al immunohistochemical analysis), these findings are consistent with those from our cell lines, demonstrating again that genomic amplification and consequent increases in amounts of transcript may be, at least in part, driving the abundance of proteins in these lung tumors. The association between expression of these genes and that of Ki-67, a known indicator of poor prognosis in lung cancer (Martin et al., 2004) , suggests that activation of these genes may be an indicator of tumor aggressiveness. These results also suggest that expression of EEF1A2 and KCIP-1 proteins in stage I non-small-cell lung cancer may be useful as a marker for distinguishing patients with relatively poor prognosis from those who might benefit from adjuvant treatment.
Discussion
Our current study illustrates the power of integrated functional genomic analyses for identifying putative oncogenes and for evaluating their potential clinical significance. Among the four identified oncogenes, three genes (PRDX1, CALR, and KCIP-1) have been implicated in lung tumorigenesis. PRDX1 is an antioxidant protein involved in regulating cell proliferation, differentiation, and apoptosis. Kim et al. (2003) found PRDX1 expression to be elevated in both lung cancer and adjacent normal lung tissue, suggesting that activation of PRDX1 may enhance proliferation in lung cancer. CALR has a major role in Ca 2 þ binding and the Only the gene showing statistically significant increased protein expression with increases in both genomic copy number and transcript simultaneously will be considered as potential putative oncogene in lung adenocarcinoma cells. b r, Spearman correlation coefficients between proteins and genomic or mRNA values are based on all six cancer cell lines; bold indicates Po0.05, if r>0.84000. Mw, molecular weight; pI, isoelectric point.
Identifying oncogenes in lung adenocarcinoma
R Li et al transcriptional regulation of other genes and was recently found to be overexpressed in 73% of 40 lung adenocarcinomas (Oates and Edwards, 2000) . KCIP-1 belongs to the 14-3-3 family, which participates via the MAPK and Wnt signaling pathways in the regulation of many cellular processes including cell proliferation and differentiation as well as tumorigenesis (Thomas et al., 2005) . KCIP-1 was recently found to be expressed in all 12 lung tumors tested in a single-institution study (Qi et al., 2005) . Interestingly, EEF1A2 was originally considered a putative oncogene in ovarian cancer on the basis of its being amplified in 25% and overexpressed in 30% of the same set of ovarian tumors (Anand et al., 2002) ; functional analyses have established its oncogenic role in cellular transformation (Lee, 2003) . Our discovery that EEF1A2 may be a putative oncogene in lung adenocarcinoma demonstrates the power of our functional genomic strategy for rapidly identifying potential oncogenes. Although the main focus of this study was to specifically identify putative oncogenes, it should be noted that 90.7% of the genes showing high protein expression did not show corresponding increases in both DNA copy number and transcript, a finding consistent with that of others that transcriptional, translational, and post-translational regulatory mechanisms can greatly influence the abundance of protein in lung tumorigenesis (Chen et al., 2002) . For example, NFKB1 is a critical arbiter of immune responses, cell survival, and transformation and is often activated in several types of tumors (Chen et al., 2002) . Deregulation of NFKB1 is thought to be modulated through phosphorylation of Ser337 by protein kinase A (Chen et al., 2002) . In our study, 68.8% of the genes showing over-representation in the genome did not show elevated transcript levels, implying that at least some of these genes are 'passenger' genes that are concurrently amplified because of their location with respect to amplicons but lack biological relevance in terms of the development of lung adenocarcinoma.
Although the potential oncogenes we identified here are likely to be important, certainly other oncogenes could be involved in the development of lung adenocarcinoma. The oligo microarray we used consists of 22 000 probes, which represent only about 60% of the human genome. Moreover, each probe was designed for the 3 0 region of expressed sequence tags of the selected genes. Also, our results were initially derived from cancer cell lines, although the findings were later confirmed in human tissue samples. Our ongoing study using microarrays with information on more genes and the development of high-resolution proteomic analyses for use with larger numbers of specimens will allow more comprehensive analyses of the molecular consequences of gene amplifications. Such expanded analyses will very likely lead to the identification of additional oncogenes.
Some of the results of our current study were comparable to those of other studies of lung cancer. For example, genomic copy number and protein levels of KCIP-1 were previously found to be amplified and overexpressed in primary lung cancers by cDNA clonebased CGH array analysis (Jiang et al., 2004) and proteomic analysis (Chen et al., 2002) , respectively. Our functional genomic approach, which integrates simultaneous CGH, transcript microarrys, proteomic analyses, and siRNA, allows us not only to quickly identify potential oncogenes but also to explore their significance as diagnostic and therapeutic targets in tumor progression -more than could be achieved by any technique alone.
Genes identified in this way may serve as promising targets for diagnosis and therapy in lung adenocarcinoma. Further research on the clinical implications of such genes is needed; experiments now underway in our laboratory include overexpression of the genes in normal cells, disruption of the function of these genes in cancer cells, and investigation of how interactions among these genes (or interactions with other known oncogenes) may mediate the expression of the transformed phenotype. Identifying oncogenes in lung adenocarcinoma R Li et al
Materials and methods

Cell lines
Six human lung adenocarcinoma cell lines (H23, H229, H1792, SK-LU-1, H522, and H1563) were obtained from the American Type Culture Collection (Manassas, VA, USA). Two normal bronchial epithelial cell lines were obtained from Clontech (Palo Alto, CA, USA). Genomic DNA, mRNA, and protein were derived from a single harvest of these cells.
DNA and RNA profiles by microarray analysis
Genomic DNA labeling and hybridization were performed as described previously (Barrett et al., 2004 ) with Agilent's Human 1A Oligo Microarray (V2) (Agilent Technologies, Palo Alto, CA, USA), which contains 22 000 unique 60-mer oligos. Details of the protocol for analysing transcripts are available at http://www.chem.agilent.com. Map positions for arrayed genes were assigned by identifying the DNA sequence represented in the UniGene cluster and matching it with the Golden Path genome assembly (http://genome.ucsc.edu/; Mat 7, 2004 Freeze). Microarray images of DNA copy number and expression were analysed by using AgilentCGH Analytics and Feature Extraction software. DNA copy number profiles that deviated significantly from background signal ratios (measured from normal control cell hybridization, as described elsewhere; Barrett et al., 2004) were interpreted as evidence of true differences in DNA copy number. The criteria for defining genomic over-representation and amplicons are described elsewhere (Hyman et al., 2002) ; details are given in the Supplementary Information. An increase in mRNA level was defined as a twofold increase in signal ratio relative to that of the control (log 2 >1).
Quantitative two-dimensional PAGE and mass spectrometry Analysis of proteins by two-dimensional PAGE and their identification by mass spectrometry were performed as previously described (Shen et al., 2004) . Briefly, protein pellets were solubilized in rehydration buffer, after which the firstdimension isoelectric focusing was carried out with a Protean IEF Cell (Bio-Rad Laboratories) and the second-dimension separation was carried out with Bio-Rad's Ready Gel Precast Gels and the Bio-Rad Criterion Cell apparatus. Protein spots were visualized by silver-based staining, and all gels were assessed with Bio-Rad's PDQuest 2D gel image analysis software. Selected spots were subjected to in-gel tryptic digestion and analysed on a Voyager-DE PRO matrix-assisted laser desorption ionization/time-of-flight mass spectrometer (Applied Biosystems, Foster City, CA, USA). The mass list of the 20 most intense monoisotopic peaks for each sample was entered in the MS-Fit search program (v3.2.1) (http:// prospector.ucsf.edu/ucsfhtml4.0/msfit.htm) and searched in the National Center for Biotechnology Information protein database.
Southern, Northern, and Western blot analyses Southern, Northern, and Western blot hybridizations were performed according to standard protocols. cDNA clones for the tested genes were purchased from Invitrogen (Carlsbad, Identifying oncogenes in lung adenocarcinoma R Li et al
